Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients. - Wikidata - wikimedia - TriplyDB

Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients.

Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients.

http://www.wikidata.org/entity/Q53334759

about

The Complexity of Targeting PI3K-Akt-mTOR Signalling in Human Acute Myeloid Leukaemia: The Importance of Leukemic Cell Heterogeneity, Neighbouring Mesenchymal Stem Cells and Immunocompetent Cells A Crowdsourcing Approach to Developing and Assessing Prediction Algorithms for AML Prognosis Anti-CD44 antibodies inhibit both mTORC1 and mTORC2: a new rationale supporting CD44-induced AML differentiation therapy.Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia.Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody Targeting signal transduction pathways to eliminate chemotherapeutic drug resistance and cancer stem cells.Puquitinib, a novel orally available PI3Kδ inhibitor, exhibits potent antitumor efficacy against acute myeloid leukemia Prophylaxis of invasive aspergillosis with voriconazole or caspofungin during building work in patients with acute leukemia.The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients.Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.AKT/FOXO signaling enforces reversible differentiation blockade in myeloid leukemias p-ERK1/2 is a predictive factor of response to erythropoiesis-stimulating agents in low/int-1 myelodysplastic syndromes.Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment.Matrine induces apoptosis in human acute myeloid leukemia cells via the mitochondrial pathway and Akt inactivation EVI1 inhibits apoptosis induced by antileukemic drugs via upregulation of CDKN1A/p21/WAF in human myeloid cells Screening for hotspot mutations in PI3K, JAK2, FLT3 and NPM1 in patients with myelodysplastic syndromes.A Hyperactive Signalosome in Acute Myeloid Leukemia Drives Addiction to a Tumor-Specific Hsp90 Species G-protein-coupled receptor agonist BV8/prokineticin-2 and STAT3 protein form a feed-forward loop in both normal and malignant myeloid cells.Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy.Rapamycin-resistant and torin-sensitive mTOR signaling promotes the survival and proliferation of leukemic cells.Heat Shock Protein 90 is overexpressed in high-risk myelodysplastic syndromes and associated with higher expression and activation of Focal Adhesion Kinase Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome.Akt1 is the principal Akt isoform regulating apoptosis in limiting cytokine concentrations.Targeting the leukemic stem cell: the Holy Grail of leukemia therapy The granulocyte-macrophage colony-stimulating factor receptor: linking its structure to cell signaling and its role in disease.Cytoplasmic localization of wild-type survivin is associated with constitutive activation of the PI3K/Akt signaling pathway and represents a favorable prognostic factor in patients with acute myeloid leukemia.Targeting PI3Kδ and PI3Kγ signalling disrupts human AML survival and bone marrow stromal cell mediated protection.Novel B55α-PP2A mutations in AML promote AKT T308 phosphorylation and sensitivity to AKT inhibitor-induced growth arrest.Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia.miRNAs in acute myeloid leukemia.Acute myeloid leukemia stem cells: seek and destroy.Evi1 forms a bridge between the epigenetic machinery and signaling pathways.Targeting phosphatidylinositol 3-kinase signaling in acute myelogenous leukemia.Perifosine--a new option in treatment of acute myeloid leukemia?Targeting PI3K/AKT/mTOR network for treatment of leukemia.Outlook on PI3K/AKT/mTOR inhibition in acute leukemia.Targeting the mTOR Pathway in Leukemia.Insights in dynamic kinome reprogramming as a consequence of MEK inhibition in MLL-rearranged AML.Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice.Synergistic effect of inhibiting translation initiation in combination with cytotoxic agents in acute myelogenous leukemia cells.

P2860

Q28074203-21C15290-30CF-44C6-967F-875016160CA0 Q28597169-547381AA-2101-4DED-890D-BCC6172A4608 Q30831849-6E1BFEE1-87F4-4996-B169-FFD6DA96F825 Q33493174-F2F66946-BA77-4E6E-8ADA-4B969DB62E37 Q33707416-80BC8234-DA8E-4DE9-89D7-25A3CDC384E7 Q33823577-56C14061-F7C3-4DEF-A961-B70AD5056FA9 Q33873323-7BB1F571-05EA-482B-B144-076C01496C9E Q33886231-06837AD8-59C0-4371-9AA2-7DB6186C758C Q34024558-65A2CDA2-AAD1-4AF4-9C1C-053D6A4518C8 Q34173253-A0F93656-D3A3-4F46-BBF5-80183F9F13D7 Q34212654-43FF3D5E-B8CF-48BA-8A13-EA9B8C0C1A9B Q34255198-669E3671-6543-458B-8AAE-FA34C2E392BE Q34260622-3C4E94DE-7DBE-4F1B-B62D-068BB6601632 Q34442297-945C2BD0-CD28-4A03-9F2E-9CC6A5065A00 Q34606698-92CB3B4A-3620-4EC2-B6DC-E9D015AC17CE Q35028968-628EDC84-7947-4A72-A90F-32464434F227 Q36426254-4511DD31-BA6A-4A47-95FC-52D8393DA78C Q36832717-FCCD92AA-5768-49C3-B6D0-47F161DD16B4 Q36973814-43050310-6ACB-476B-B8AD-D89416C9BC8A Q37021907-8E5F102C-8ECC-4BD3-B6B8-2B947D1D4D25 Q37031282-5ACBF446-8B15-4FAC-A1EE-82A5A5CE9F2C Q37046021-FA9BE7FA-E1F7-46F4-B5AD-4095C31E40E0 Q37163727-BE41E1FC-5893-4E97-9F5F-B978EBE7B420 Q37272565-88AD06FF-7029-418B-93A3-E48567A5256C Q37306641-4EBAA80A-4FCB-4F91-9240-146F7CEB617C Q37377906-54E2BD66-F490-4EBA-B2EF-5C4A73861104 Q37457673-4E2F1D8D-E0FA-400B-80AB-401E996111AB Q37641562-861EA9F5-981C-4FB7-B767-18D9BBAD023E Q37642294-13833617-BAD3-4BA9-AA0A-2737D174993E Q37709531-EFB701E7-A6D2-4539-BCFA-282F154FFF20 Q37810086-71DA71A7-739D-4BEB-A4A1-3C5BEFD6AC1C Q37906986-A62185D2-42F6-41AC-8A26-D8936680981C Q38113583-C245F014-3919-43A9-B60C-AB9B6993C2D1 Q38127844-3DA29861-B750-416C-BF58-B1F3B05C3B54 Q38364871-2838203B-2A5C-42D1-8CC4-5D114FB856DE Q38521775-3CD41CB2-FB78-4D58-A9A6-E2382F2C6569 Q38790630-084FD84D-1C69-46A1-AFCD-B686089068D5 Q39062437-8A6CB04B-1E0E-4287-851B-DA2727759B65 Q39206146-B31675AB-1522-4F90-ADA0-6ABEAE0743D0 Q39804531-042B568F-2D3A-45C8-8920-2A0483B2FF2E

P2860

Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients.

http://www.wikidata.org/entity/Q53334759

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

2007年學術文章

@zh-hant

name

Constitutive phosphoinositide ...... myelogenous leukemia patients.

@en

Constitutive phosphoinositide ...... myelogenous leukemia patients.

@nl

type

label

Constitutive phosphoinositide ...... myelogenous leukemia patients.

@en

Constitutive phosphoinositide ...... myelogenous leukemia patients.

@nl

prefLabel

Constitutive phosphoinositide ...... myelogenous leukemia patients.

@en

Constitutive phosphoinositide ...... myelogenous leukemia patients.

@nl

P1433

Q53334759-B5C387D3-E86A-4E65-9B0C-826BB375A321

P1476

Q53334759-217E1057-6896-43A8-B227-89B9E65C85C8

P2093

Q53334759-3FABD80E-4014-40B1-81A1-C096B1F5C100

Q53334759-4FC7BF82-A5A7-4C30-93E1-CE35DAD5379C

Q53334759-597BD551-38BC-4479-BF4E-5431A9EEDED0

Q53334759-5EA5185D-6B4B-45D9-BD90-C65D641232D5

Q53334759-61C1A2D5-67E5-401E-88E6-7D5D40EFCEF2

Q53334759-B07E722A-A0ED-4DB5-B004-2FE1DDAB0A82

Q53334759-C3B8B665-2E4B-435D-A628-489BF53F8851

Q53334759-C9622B84-D8B5-4EB5-847C-2C0B8049B986

Q53334759-D30FDA5B-7E19-4A8D-AA55-EA025679A106

Q53334759-E9B0A57F-13C1-4D23-A0DF-95DD984C8D0A

P304

Q53334759-8136F25E-CA41-42E9-AC15-082D3FDD6C08

P31

Q53334759-9CFCAF83-940F-4038-8E27-FEA76E7B7F38

P356

Q53334759-6AB4A58F-DFE9-4D56-886C-0B6D303D2FDE

P407

Q53334759-99F3EE9F-EB33-4F8D-976E-31FAF2C41DAC

P433

Q53334759-838CA728-D591-484A-8213-E6FAD4E43102

P478

Q53334759-330751BB-7184-4CFB-AFBD-AE7EA99223FA

P50

Q53334759-5BE15376-93DB-462F-A833-3BF22E32A173

Q53334759-6F7E6E4D-BE1A-4859-A16A-CB7744E09E5A

Q53334759-74102B08-6188-4AF3-94BF-64D46DE0EA2D

Q53334759-7CB8B444-D1EF-4C52-9C2F-8024C7011C14

Q53334759-AD897A22-4B62-4666-92C3-0DB73CC5E42F

Q53334759-F31B42E1-3183-4473-8F0B-B90277240D1B

P577

Q53334759-C49C1D4E-265D-4AFA-8F78-0A76B4652581

P5875

Q53334759-FA093037-4705-4892-932D-02F35C309674

P698

Q53334759-9A8E51CB-FEBE-4B7F-96F9-34589B03343A

P921

Q53334759-85404C5D-1A3E-441E-BA8A-2DDBFC0E872B

P356

BLOOD-2006-12-061283

P1433

P1476

Constitutive phosphoinositide ...... myelogenous leukemia patients

@en

P2093

Bruno Lioure

http://www.w3.org/2001/XMLSchema#string

Caroline Elie

http://www.w3.org/2001/XMLSchema#string

Catherine Lacombe

http://www.w3.org/2001/XMLSchema#string

Francis Witz

http://www.w3.org/2001/XMLSchema#string

François Dreyfus

http://www.w3.org/2001/XMLSchema#string

Odile Blanchet

http://www.w3.org/2001/XMLSchema#string

Pascale Cornillet-Lefebvre

http://www.w3.org/2001/XMLSchema#string

Patrick Mayeux

http://www.w3.org/2001/XMLSchema#string

Sophie Park

http://www.w3.org/2001/XMLSchema#string

Valérie Ugo

http://www.w3.org/2001/XMLSchema#string

P304

1025-1028

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2006-12-061283

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

110

http://www.w3.org/2001/XMLSchema#string

P50

Jerome Tamburini

Didier Bouscary

Nicolas Chapuis

Valérie Bardet

P577

2007-04-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51390412

http://www.w3.org/2001/XMLSchema#string

P698

17426258

http://www.w3.org/2001/XMLSchema#string

P921